Averion and Brazil-Based CRO BIOCANCER Sign Strategic Alliance Agreement.

Averion To Initiate Oncology Offering In South America 

BOSTON -- Averion International Corp. (OTCBB:AVRO) and Brazil-based BIOCANCER today announced the signing of a non-exclusive agreement to jointly market and contract complementary services to biotechnology, pharmaceutical and medical device companies. BIOCANCER is a full-service site management and clinical research organization (CRO) with a focus on oncology.

"This agreement expands our reach to South America, providing us with access to leading clinical sites and large patient populations," said Philip Lavin, PhD, Averion International Chief Executive Officer. "In line with our strategy to achieve rapid market growth, we plan to continue building on our international oncology CRO offering through strategic partnerships and acquisitions. BIOCANCER has established relationships with highly qualified and experienced personnel and we are pleased to partner with BIOCANCER as we grow our oncology CRO offering."

"As we help our clients plan and implement global development for new oncology agents, this alliance allows us to expand our sponsors' cost-effective access to high-quality medical facilities that can access common as well as rare forms of cancer," said Gene Resnick, MD, Averion International Chief Medical Officer.

Carlos Guimaraes, BIOCANCER CEO, noted, "Our relationship with Averion will help fulfill our goal at BIOCANCER of offering significant value in global oncology trials by providing superior clinical research support through our alliance with a recognized leader in oncology development."

About BIOCANCER

BIOCANCER is an oncology-focused drug development services company that assists pharmaceutical, biotechnology, medical device and drug development services companies in accessing Brazil's large patient populations. The company is based in Belo Horizonte, Brazil's third largest city. BIOCANCER's service offerings include patient and investigator recruitment; clinical trial planning; regulatory support; protocol design and review; database design; data entry and verification; pharmacokinetic and statistical analysis; and the generation of clinical trial reports, manuscripts and abstracts. For more information visit www.biocancer.com.br.

About Averion International Corp.

Averion International Corp. is a full service clinical research organization (CRO) that provides clinical research and staffing services to the pharmaceutical, biotechnology and medical device/diagnostic industries. The Company has a therapeutic focus in oncology, medical devices, dermatology, and nephrology. Averion's clinical research core competencies are in FDA and product registration support, site selection, project management, medical and site monitoring, data management, biometrics, pharmacovigilance, medical writing, and full clinical trial management services throughout the clinical trials lifecycle. The Company has supported FDA approvals for products in many therapeutic areas including: oncology, medical devices, dermatology, and nephrology. The Company also provides staffing services to help solve many regulatory and validation problems faced by clients throughout the product development lifecycle.

Averion is headquartered in Southborough, Mass. and has additional U.S. office locations in New York, Philadelphia and San Diego, as well as European offices in Germany, United Kingdom, Austria and operations in Poland. For more information, visit www.averionintl.com.

Forward-Looking Statement 

Statements contained in this press release that are not historical information are forward-looking statements as defined within the Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by the use of words such as "believe," "expect," "anticipate," "intend," "plan," "estimate," "project," or words of similar meaning, or future or conditional verbs such as "will," "would," "should," "could," or "may." Such forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from those projected or implied. Those risks and uncertainties include, but are not limited to: our ability to attract, retain or integrate key personnel, including scientific and technical personnel; the termination, modification or delay of contracts which would, among other things, adversely impact our recognition of revenue included in backlog; risks associated with our pursuit of strategic acquisitions or investment in new markets; our ability to acquire and integrate new businesses; our dependence on certain industries and clients; our ability to adequately protect sensitive patient information and confidential information of clients; our ability to keep pace with rapid technological changes; fluctuation in our operating results; our ability to recruit suitable volunteers for the clinical trials of our clients; our exposure to exchange rate fluctuations and international economic, political and other risks; our ability to develop and market new services in the U.S., Europe and internationally; the highly competitive nature of our market; our exposure to changes in outsourcing trends in the pharmaceutical and biotechnology industries; the impact of government regulation on our business; whether we can achieve and maintain effective internal controls; and other risks. Certain of these risks and uncertainties, in addition to other risks, are more fully described in the Company's annual report on Form 10-KSB for the period ending December 31, 2006 and in the Company's other periodic reports filed with the Securities and Exchange Commission. These forward-looking statements are made only as of the date of this press release, and the Company assumes no obligation to update or revise the forward-looking statements, whether as a result of new information, future events, or otherwise.